TD Cowen analysts questioned about revenue decline, while Goldman Sachs inquired about business development.
1 report, 0 independent
Updated Jun 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
TD Cowen analysts questioned about revenue decline, while Goldman Sachs inquired about business development.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
TD Cowen
American investment bank
-
BioMarin Pharmaceutical
American company
Nothing else this week.
-
Goldman Sachs
American investment bank
Related events
- TD Cowen provided research reports on Adaptive Biotechnologies on August 1, 2026.
- Major U.S. banks JPMorgan Chase and Goldman Sachs reported earnings, and TD Cowen initiated a buy rating on Goldman Sachs.
- Analyst targets are being lowered amid new entrants challenging market dominance for medical technology companies.
- Multiple financial firms, including TD Cowen, Goldman Sachs, and Mizuho, issued various rating changes and price target updates across several stocks.
Coverage
Newest first; wire copies grouped- Unknown outlet